European Crohn´s and Colitis Organisation - ECCO - OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical M
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease | Gastroenterología y Hepatología (English Edition)
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease - Clinical Gastroenterology and Hepatology
Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients | Scientific Reports
PDF) Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial
Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease - Gastroenterology
Frontiers | Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 | SpringerLink
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? | Nature Reviews Gastroenterology & Hepatology
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
Adalimumab | ECCO E-Guide
PDF) Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: Medical treatment
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study - The Lancet Gastroenterology & Hepatology
Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost‐effectiveness analysis - Yao - 2021 - Journal of Gastroenterology and Hepatology - Wiley Online Library
European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) - Gastroenterology
European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
Neel Heerasing (@gastrodr_nh) / Twitter
